Novel molecular aspects of ghrelin and leptin in the control of adipobiology and the cardiovascular system

Obesity Facts

Volumn 7, Issue 2, 2014, Pages 82-95

  Rodríguez, Amaia ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adipocyte; Adipokines; Appetite; Blood pressure; Cardiometabolic risk; Cardiovascular disorders; Energy balance; Ghrelin; GOAT; Hypertension

Indexed keywords

ADIPOCYTOKINE; ANGIOTENSIN II; AQUAGLYCEROPORIN; CALCIUM ION; FAT DROPLET; GHRELIN; GLYCEROL; INDUCIBLE NITRIC OXIDE SYNTHASE; LEPTIN; LEPTIN RECEPTOR; PERILIPIN; ADENOSINE DEAMINASE; AQUAPORIN 3; AQUAPORIN 7; AQUAPORIN 9; CALCIUM; MAMMALIAN TARGET OF RAPAMYCIN; NEUROPEPTIDE Y; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; APOPTOSIS; AUTOPHAGY; BLOOD VESSEL WALL; BODY WEIGHT; CARDIOMETABOLIC RISK; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; CYTOSOLIC FRACTION; ENERGY BALANCE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HOMEOSTASIS; HUMAN; LIPID STORAGE; METABOLIC SYNDROME X; NERVE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; VASODILATATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL MEMBRANE; DIASTOLIC DYSFUNCTION; ENERGY EXPENDITURE; FAT MASS; HEART OUTPUT; HEART VENTRICLE REMODELING; LIPOLYSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYMPATHETIC TONE; SYSTEMIC VASCULAR RESISTANCE; INFLAMMATION; LIPID METABOLISM; METABOLISM;

ADIPOSE TISSUE; ADIPOSITY; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; GHRELIN; HUMANS; INFLAMMATION; LEPTIN; LIPID METABOLISM; OBESITY;

EID: 84897119503     PISSN: 16624025     EISSN: 16624033     Source Type: Journal    
DOI: 10.1159/000360837     Document Type: Review

References (108)

1. Frühbeck G, Toplak H, Woodward E, Yumuk V, Maislos M, Oppert JM: Obesity: The gateway to ill health - an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts 2013; 6: 117-120.
2. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al: National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557-567.
3. Rodríguez A, Catalán V, Gómez-Ambrosi J, Frühbeck G. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Curr Pharm Des 2007; 13: 2169-2175
4. Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R: Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) 2006; 14: 336-341.
5. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al: Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649.
6. Frühbeck G: The adipose tissue as a source of vasoactive factors. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 197-208.
7. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
8. Frühbeck G, Diez Caballero A, Gil MJ: Fundus functionality and ghrelin concentrations after bariatric surgery. N Engl J Med 2004; 350: 308-309.
9. Chen CY, Asakawa A, Fujimiya M, Lee SD, Inui A: Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev 2009; 61: 430-481.
10. Zhu X, Cao Y, Voogd K, Steiner DF: On the processing of proghrelin to ghrelin. J Biol Chem 2006; 281: 38867-38870.
11. Hosoda H, Kojima M, Matsuo H, Kangawa K: Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 2000; 279: 909-913.
12. Campana D, Nori F, Pagotto U, De Iasio R, Morselli-Labate AM, Pasquali R, et al: Plasma acylated ghrelin levels are higher in patients with chronic atrophic gastritis. Clin Endocrinol (Oxf) 2007; 67: 761-766.
13. Tong J, Dave N, Mugundu GM, Davis HW, Gaylinn BD, Thorner MO, et al: The pharmacokinetics of acyl, des-acyl, and total ghrelin in healthy human subjects. Eur J Endocrinol 2013; 168; 821-828.
14. Pacifico L, Poggiogalle E, Costantino F, Anania C, Ferraro F, Chiarelli F, et al: Acylated and nonacylated ghrelin levels and their associations with insulin resistance in obese and normal weight children with metabolic syndrome. Eur J Endocrinol 2009; 161: 861-870.
15. Koyama KI, Yasuhara D, Nakahara T, Harada T, Uehara M, Ushikai M, et al: Changes in acyl ghrelin, des-acyl ghrelin, and ratio of acyl ghrelin to total ghrelin with short-term refeeding in female inpatients with restrictingtype anorexia nervosa. Horm Metab Res 2010; 42: 595-598.
16. Naufel MF, Bordon M, de Aquino TM, Ribeiro EB, de Abreu Carvalhaes JT: Plasma levels of acylated and total ghrelin in pediatric patients with chronic kidney disease. Pediatr Nephrol 2010; 25: 2477-2482.
17. Hosoda H, Kojima M, Matsuo H, Kangawa K: Purification and characterization of rat des-Gln14-Ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor. J Biol Chem 2000; 275: 21995-22000.
18. Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL: Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008; 132: 387-396.
19. Rodríguez A, Gómez-Ambrosi J, Catalán V, Rotellar F, Valenti V, Silva C, et al: The ghrelin O -acyltransferaseghrelin system reduces TNF-alpha-induced apoptosis and autophagy in human visceral adipocytes. Diabetologia 2012; 55: 3038-3050.
20. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974-977.
21. Tanaka M, Miyazaki T, Yamamoto I, Nakai N, Ohta Y, Tsushima N, et al: Molecular characterization of chicken growth hormone secretagogue receptor gene. Gen Comp Endocrinol 2003; 134: 198-202.
22. Leung PK, Chow KB, Lau PN, Chu KM, Chan CB, Cheng CH, et al: The truncated ghrelin receptor polypeptide (GHS-R1b) acts as a dominant-negative mutant of the ghrelin receptor. Cell Signal 2007; 19: 1011-1022.
23. Müller TD, Müller A, Yi CX, K MH, Meyer CW, Gaylinn BD, et al: The orphan receptor Gpr83 regulates systemic energy metabolism via ghrelin-dependent and ghrelin-independent mechanisms. Nat Commun 2013; 4: 1968.
24. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
25. Gautron L, Elmquist JK: Sixteen years and counting: an update on leptin in energy balance. J Clin Invest 2011; 121: 2087-2093.
26. Madej T, Boguski MS, Bryant SH: Threading analysis suggests that the obese gene product may be a helical cytokine. FEBS Lett 1995; 373: 13-18.
27. Kline AD, Becker GW, Churgay LM, Landen BE, Martin DK, Muth WL, et al: Leptin is a four-helix bundle: secondary structure by NMR. FEBS Lett 1997; 407: 239-242.
28. Rock FL, Altmann SW, van Heek M, Kastelein RA, Bazan JF: The leptin haemopoietic cytokine fold is stabilized by an intrachain disulfide bond. Horm Metab Res 1996; 28: 649-652.
29. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al: Serum immunoreactiveleptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
30. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, et al: Decreased cerebrospinalfluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348: 159-161.
31. Licinio J, Negrao AB, Mantzoros C, Kaklamani V, Wong ML, Bongiorno PB, et al: Sex differences in circulating human leptin pulse amplitude: clinical implications. J Clin Endocrinol Metab 1998; 83: 4140-4147.
32. Frühbeck G: Intracellular signalling pathways activated by leptin. Biochem J 2006; 393: 7-20.
33. Gómez-Ambrosi J, Rodríguez A, Catalán V, Frühbeck G: The bone-adipose axis in obesity and weight loss. Obes Surg 2008; 18: 1134-1143.
34. Blouet C, Schwartz GJ: Hypothalamic nutrient sensing in the control of energy homeostasis. Behav Brain Res 2010; 209: 1-12.
35. Harvey J, Ashford ML: Leptin in the CNS: much more than a satiety signal. Neuropharmacology 2003; 44: 845-854.
36. Scarpace PJ, Matheny M, Pollock BH, Tumer N: Leptin increases uncoupling protein expression and energy expenditure. Am J Physiol 1997; 273:E226-230.
37. Becerril S, Rodríguez A, Catalán V, Sáinz N, Ramírez B, Collantes M, et al: Deletion of inducible nitric-oxide synthase in leptin-deficient mice improves brown adipose tissue function. PLoS One 2010; 5:e10962.
38. Becerril S, Rodríguez A, Catalán V, Sáinz N, Ramírez B, Gómez-Ambrosi J, et al: Transcriptional analysis of brown adipose tissue in leptin-deficient mice lacking inducible nitric oxide synthase: evidence of the role of Med1 in energy balance. Physiol Genomics 2012; 44: 678-688.
39. Frühbeck G, Gómez-Ambrosi J, Salvador J: Leptin-induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes. FASEB J 2001; 15: 333-340.
40. Rodríguez A, Catalán V, Gómez-Ambrosi J, Frühbeck G: Role of aquaporin-7 in the pathophysiological control of fat accumulation in mice. FEBS Lett 2006; 580: 4771-4776.
41. Rodríguez A, Catalán V, Gómez-Ambrosi J, Frühbeck G: Aquaglyceroporins serve as metabolic gateways in adiposity and insulin resistance control. Cell Cycle 2011; 10: 1548-1556.
42. Rodríguez A, Catalán V, Gómez-Ambrosi J, García-Navarro S, Rotellar F, Valentí V, et al: Insulin- and leptinmediated control of aquaglyceroporins in human adipocytes and hepatocytes is mediated via the PI3K/Akt/mTOR signaling cascade. J Clin Endocrinol Metab 2011; 96:E586-597.
43. Yasui H, Kubota M, Iguchi K, Usui S, Kiho T, Hirano K: Membrane trafficking of aquaporin 3 induced by epinephrine. Biochem Biophys Res Commun 2008; 373: 613-617.
44. Walker CG, Holness MJ, Gibbons GF, Sugden MC: Fasting-induced increases in aquaporin 7 and adipose triglyceride lipase mRNA expression in adipose tissue are attenuated by peroxisome proliferator-activated receptor alpha deficiency. Int J Obes(Lond) 2007; 31: 1165-1171.
45. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-1719.
46. Toshinai K, Date Y, Murakami N, Shimada M, Mondal MS, Shimbara T, et al: Ghrelin-induced food intake is mediated via the orexin pathway. Endocrinology 2003; 144: 1506-1512.
47. Chen HY, Trumbauer ME, Chen AS, Weingarth DT, Adams JR, Frazier EG, et al: Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 2004; 145: 2607-2612.
48. López M, Lage R, Saha AK, Pérez-Tilve D, Vézquez MJ, Varela L, et al: Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab 2008; 7: 389-399.
49. Velásquez DA, Martínez G, Romero A, Vázquez MJ, Boit KD, Dopeso-Reyes IG, et al: The central Sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin. Diabetes 2011; 60: 1177-1185.
50. Martins L, Fernández-Mallo D, Novelle MG, Vázquez MJ, Tena-Sempere M, Nogueiras R, et al: Hypothalamic mTOR signaling mediates the orexigenic action of ghrelin. PLoS One 2012; 7:e46923.
51. Tschöp M, Weyer C, Tataranni A, Devanarayan V, Ravussin E, Heiman ML: Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-709.
52. Poykko SM, Ukkola O, Kauma H, Kellokoski E, Horkko S, Kesaniemi YA: The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes. Diabetologia 2005; 48: 309-316.
53. Rodríguez A, Gómez-Ambrosi J, Catalán V, Gil MJ, Becerril S, Sáinz N, et al: Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes (Lond) 2009; 33: 541-552.
54. Rodríguez A, Gómez-Ambrosi J, Catalán V, Becerril S, Sáinz N, Gil MJ, et al: Association of plasma acylated ghrelin with blood pressure and left ventricular mass in patients with metabolic syndrome. J Hypertens 2010; 28: 560-567.
55. Barazzoni R, Zanetti M, Nagliati C, Cattin MR, Ferreira C, Giuricin M, et al: Gastric bypass does not normalize obesity-related changes in ghrelin profile and leads to higher acylated ghrelin fraction. Obesity (Silver Spring) 2013; 21: 718-722.
56. Catalán V, Gómez-Ambrosi J, Rotellar F, Silva C, Gil MJ, Rodríguez A, et al: The obestatin receptor (GPR39) is expressed in human adipose tissue and is down-regulated in obesity-associated type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007; 66: 598-601.
57. Gurriarán-Rodríguez U, Al-Massadi O, Crujeiras AB, Mosteiro CS, Amil-Diz M, Beiroa D, et al: Preproghrelin expression is a key target for insulin action on adipogenesis. J Endocrinol 2011; 210:R1-7.
58. Benso A, St-Pierre DH, Prodam F, Gramaglia E, Granata R, van der Lely AJ, et al: Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans. Eur J Endocrinol 2012; 166: 911-916.
59. Miegueu P, St Pierre D, Broglio F, Cianflone K: Effect of desacyl ghrelin, obestatin and related peptides on triglyceride storage, metabolism and GHSR signaling in 3T3-L1 adipocytes. J Cell Biochem 2011; 112: 704-714.
60. Eckel RH, Krauss RM: American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998; 97: 2099-2100.
61. Kopelman PG: Obesity as a medical problem. Nature 2000; 404: 635-643.
62. Algahim MF, Sen S, Taegtmeyer H: Bariatric surgery to unload the stressed heart: a metabolic hypothesis. Am J Physiol Heart Circ Physiol 2012; 302:H1539-1545.
63. Rahmouni K, Correia ML, Haynes WG, Mark AL: Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45: 9-14.
64. Frühbeck G: Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999; 48: 903-908.
65. Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, d'Amati G, et al: Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000; 49: 293-297.
66. Beltowski J, Wojcicka G, Jamroz-Wisniewska A, Marciniak A: Resistance to acute NO-mimetic and EDHFmimetic effects of leptin in the metabolic syndrome. Life Sci 2009; 85: 557-567.
67. Gálvez B, de Castro J, Herold D, Dubrovska G, Arribas S, González MC, et al: Perivascular adipose tissue and mesenteric vascular function in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 2006; 26: 1297-1302.
68. Dunbar JC, Hu Y, Lu H: Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes 1997; 46: 2040-2043.
69. Vecchione C, Maffei A, Colella S, Aretini A, Poulet R, Frati G, et al: Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002; 51: 168-173.
70. Rodríguez A, Fortuño A, Gómez-Ambrosi J, Zalba G, Díez J, Frühbeck G: The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism. Endocrinology 2007; 148: 324-331.
71. Fortuño A, Rodríguez A, Gómez-Ambrosi J, Muñiz P, Salvador J, Díez J, et al: Leptin inhibits angiotensin II-induced intracellular calcium increase and vasoconstriction in the rat aorta. Endocrinology 2002; 143: 3555-3560.
72. Villarreal D, Reams G, Samar H, Spear R, Freeman RH: Effects of chronic nitric oxide inhibition on the renal excretory response to leptin. Obes Res 2004; 12: 1006-1010.
73. Wold LE, Relling DP, Duan J, Norby FL, Ren J: Abrogated leptin-induced cardiac contractile response in ventricular myocytes under spontaneous hypertension: role of Jak/STAT pathway. Hypertension 2002; 39: 69-74.
74. Rodríguez A, Frühbeck G, Gómez-Ambrosi J, Catalán V, Sáinz N, Díez J, et al: The inhibitory effect of leptin on angiotensin II-induced vasoconstriction is blunted in spontaneously hypertensive rats. J Hypertens 2006; 24: 1589-1597.
75. Henriksen JH, Holst JJ, Moller S, Andersen UB, Bendtsen F, Jensen G: Elevated circulating leptin levels in arterial hypertension: relationship to arteriovenous overflow and extraction of leptin. Clin Sci (Lond) 2000; 99: 527-534.
76. Agata J, Masuda A, Takada M, Higashiura K, Murakami H, Miyazaki Y, et al: High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 1997; 10: 1171-1174.
77. Rodríguez A, Gómez-Ambrosi J, Catalán V, Fortuño A, Frühbeck G: Leptin inhibits the proliferation of vascular smooth muscle cells induced by angiotensin II through nitric oxide-dependent mechanisms. Mediators Inflamm 2010; 2010: 105489.
78. Schroeter MR, Stein S, Heida NM, Leifheit-Nestler M, Cheng IF, Gogiraju R, et al: Leptin promotes the mobilization of vascular progenitor cells and neovascularization by NOX2-mediated activation of MMP9. Cardiovasc Res 2012; 93: 170-180.
79. Rodríguez A, Catalán V, Becerril S, Gil MJ, Mugueta C, Gómez-Ambrosi J, et al: Impaired adiponectin-AMPK signalling in insulin-sensitive tissues of hypertensive rats. Life Sci 2008; 83: 540-549.
80. Oda A, Taniguchi T, Yokoyama M: Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 2001; 47: 141-150.
81. Schroeter MR, Leifheit-Nestler M, Hubert A, Schumann B, Gluckermann R, Eschholz N, et al: Leptin promotes neointima formation and smooth muscle cell proliferation via NADPH oxidase activation and signalling in caveolin-rich microdomains. Cardiovasc Res 2013; 99: 555-565.
82. Bohlen F, Kratzsch J, Mueller M, Seidel B, Friedman-Einat M, Witzigmann H, et al: Leptin inhibits cell growth of human vascular smooth muscle cells. Vascul Pharmacol 2007; 46: 67-71.
83. Trovati M, Doronzo G, Barale C, Vaccheris C, Russo I, Cavalot F: Leptin and Vascular Smooth Muscle Cells. Curr Pharm Des 2014; 20: 625-634.
84. Lin Y, Matsumura K, Fukuhara M, Kagiyama S, Fujii K, Iida M: Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 2004; 43: 977-982.
85. Matsumura K, Tsuchihashi T, Fujii K, Abe I, Iida M: Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 2002; 40: 694-699.
86. Iglesias MJ, Pineiro R, Blanco M, Gallego R, Diéguez C, Gualillo O, et al: Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res 2004; 62: 481-488.
87. Beiras-Fernández A, Kreth S, Weis F, Ledderose C, Pottinger T, Diéguez C, et al: Altered myocardial expression of ghrelin and its receptor (GHSR-1a) in patients with severe heart failure. Peptides 2010; 31: 2222-2228.
88. Mao Y, Tokudome T, Otani K, Kishimoto I, Miyazato M, Kangawa K: Excessive sympathoactivation and deteriorated heart function after myocardial infarction in male ghrelin knockout mice. Endocrinology 2013; 154: 1854-1863.
89. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, et al: Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104: 1430-1435.
90. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, et al: Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110: 3674-3679.
91. Schwenke DO, Tokudome T, Kishimoto I, Horio T, Cragg PA, Shirai M, et al: One dose of ghrelin prevents the acute and sustained increase in cardiac sympathetic tone after myocardial infarction. Endocrinology 2012; 153: 2436-2443.
92. Bedendi I, Alloatti G, Marcantoni A, Malan D, Catapano F, Ghe C, et al: Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin an des-Gln14-ghrelin. Eur J Pharmacol 2003; 476: 87-95.
93. Ma Y, Zhang L, Edwards JN, Launikonis BS, Chen C: Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium. PLoS One 2012; 7:e35265.
94. Rodríguez A, Gómez-Ambrosi J, Catalán V, Becerril S, Sáinz N, Ramírez B, et al: Vasodilator effect of ghrelin in the rat aorta. Endocrinol Nutr 2008; 55: 448-453.
95. Kawczynska-Drozdz A, Olszanecki R, Jawien J, Brzozowski T, Pawlik WW, Korbut R, et al: Ghrelin inhibits vascular superoxide production in spontaneously hypertensive rats. Am J Hypertens 2006; 19: 764-767.
96. Tesauro M, Schinzari F, Rovella V, Di Daniele N, Lauro D, Mores N, et al: Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension 2009; 54: 995-1000.
97. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, et al: Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002; 159: 1029-1037.
98. Yang C, Wang Y, Liu H, Li N, Sun Y, Liu Z, et al: Ghrelin protects H9c2 cardiomyocytes from angiotensin II-induced apoptosis through the endoplasmic reticulum stress pathway. J Cardiovasc Pharmacol 2012; 59: 465-471.
99. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, et al: Ghrelin inhibits proinflammatory responses and nuclear factor-κB activation in human endothelial cells. Circulation 2004; 109: 2221-2226.
100. Cao Y, Tang J, Yang T, Ma H, Yi D, Gu C, et al: Cardioprotective effect of ghrelin in cardiopulmonary bypass involves a reduction in inflammatory response. PLoS One 2013; 8:e55021.
101. Aydin S, Guzel SP, Kumru S, Akin O, Kavak E, Sahin I, et al: Serum leptin and ghrelin concentrations of maternal serum, arterial and venous cord blood in healthy and preeclamptic pregnant women. J Physiol Biochem 2008; 64: 51-59.
102. Oner-Iyidogan Y, Kocak H, Gurdol F, Oner P, Issever H, Esin D: Circulating ghrelin levels in obese women: a possible association with hypertension. Scand J Clin Lab Invest 2007; 67: 568-576.
103. Yang D, Liu Z, Luo Q: Plasma ghrelin and pro-inflammatory markers in patients with obstructive sleep apnea and stable coronary heart disease. Med Sci Monit 2013; 19: 251-256.
104. Vörös K, Prohászka Z, Kaszás E, Alliquander A, Terebesy A, Horváth F, et al: Serum ghrelin level and TNFalpha/ghrelin ratio in patients with previous myocardial infarction. Arch Med Res 2012; 43: 548-554.
105. Uchegbu EC, Kopelman PG: Cardiovascular risks in obesity. J Endocrinol Invest 2002; 25: 915-918.
106. Rodríguez A, Becerril S, Valentí V, Ramírez B, Martín M, Méndez-Giménez L, et al: Sleeve gastrectomy reduces blood pressure in obese (fa/fa) Zucker rats. Obes Surg 2012; 22: 309-315.
107. Rodríguez A, Becerril S, Valentí V, Moncada R, Méndez-Giménez L, Ramírez B, et al: Short-term effects of sleeve gastrectomy and caloric restriction on blood pressure in diet-induced obese rats. Obes Surg 2012; 22: 1481-1490.
108. Prior LJ, Davern PJ, Burke SL, Lim K, Armitage JA, Head GA: Exposure to a high-fat diet during development alters leptin and ghrelin sensitivity and elevates renal sympathetic nerve activity and arterial pressure in rabbits. Hypertension 2014; 63: 338-345.